Illumina Inc. (ILMN)

$120.43

+3.13

(+2.67%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $117.79
    $123.83
    $120.43
    downward going graph

    2.19%

    Downside

    Day's Volatility :4.88%

    Upside

    2.75%

    downward going graph
  • $84.06
    $184.79
    $120.43
    downward going graph

    30.2%

    Downside

    52 Weeks Volatility :54.51%

    Upside

    34.83%

    downward going graph

Returns

PeriodIllumina Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-4.07%
6.5%
7.9%
6 Months
-16.59%
7.1%
11.2%
1 Year
-38.65%
9.8%
21.6%
3 Years
-76.13%
14.2%
15.8%

Highlights

Market Capitalization
18.5B
Book Value
$36.06
Earnings Per Share (EPS)
-8.15
PEG Ratio
4.3
Wall Street Target Price
142.29
Profit Margin
-28.71%
Operating Margin TTM
-5.48%
Return On Assets TTM
-0.5%
Return On Equity TTM
-20.76%
Revenue TTM
4.5B
Revenue Per Share TTM
28.39
Quarterly Revenue Growth YOY
-1.0%
Gross Profit TTM
3.1B
EBITDA
345.0M
Diluted Eps TTM
-8.15
Quarterly Earnings Growth YOY
-0.96
EPS Estimate Current Year
3.91
EPS Estimate Next Year
4.73
EPS Estimate Current Quarter
0.04
EPS Estimate Next Quarter
0.15

Analyst Recommendation

Buy
    46%Buy
    43%Hold
    10%Sell
Based on 30 Wall street analysts offering stock ratings for Illumina Inc.(by analysts ranked 0 to 5 stars)
Based on 30 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
14
Hold
13
13
13
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 18.15%

Current $120.43
Target $142.29

Company Financials

FY18Y/Y Change
Revenue
3.3B
↑ 21.11%
Net Income
826.0M
↑ 13.77%
Net Profit Margin
24.78%
↓ 1.6%
FY19Y/Y Change
Revenue
3.5B
↑ 6.3%
Net Income
1.0B
↑ 21.31%
Net Profit Margin
28.28%
↑ 3.5%
FY20Y/Y Change
Revenue
3.2B
↓ 8.58%
Net Income
656.0M
↓ 34.53%
Net Profit Margin
20.25%
↓ 8.03%
FY21Y/Y Change
Revenue
4.5B
↑ 39.73%
Net Income
762.0M
↑ 16.16%
Net Profit Margin
16.84%
↓ 3.41%
FY22Y/Y Change
Revenue
4.6B
↑ 1.28%
Net Income
-4.4B
↓ 677.95%
Net Profit Margin
-96.07%
↓ 112.91%
FY23Y/Y Change
Revenue
4.5B
↓ 1.75%
Net Income
-1.2B
↓ 73.64%
Net Profit Margin
-25.78%
↑ 70.29%
Q4 FY22Q/Q Change
Revenue
1.1B
↓ 2.78%
Net Income
-140.0M
↓ 96.33%
Net Profit Margin
-12.92%
↑ 329.32%
Q1 FY23Q/Q Change
Revenue
1.1B
↑ 0.28%
Net Income
3.0M
↓ 102.14%
Net Profit Margin
0.28%
↑ 13.2%
Q2 FY23Q/Q Change
Revenue
1.2B
↑ 8.19%
Net Income
-234.0M
↓ 7900.0%
Net Profit Margin
-19.9%
↓ 20.18%
Q3 FY23Q/Q Change
Revenue
1.1B
↓ 4.85%
Net Income
-754.0M
↑ 222.22%
Net Profit Margin
-67.38%
↓ 47.48%
Q4 FY23Q/Q Change
Revenue
1.1B
↑ 0.27%
Net Income
-176.0M
↓ 76.66%
Net Profit Margin
-15.69%
↑ 51.69%
Q1 FY24Q/Q Change
Revenue
1.1B
↓ 4.1%
Net Income
-126.0M
↓ 28.41%
Net Profit Margin
-11.71%
↑ 3.98%
FY18Y/Y Change
Total Assets
7.0B
↑ 32.38%
Total Liabilities
3.1B
↑ 29.05%
FY19Y/Y Change
Total Assets
7.3B
↑ 5.13%
Total Liabilities
2.7B
↓ 13.2%
FY20Y/Y Change
Total Assets
7.6B
↑ 3.68%
Total Liabilities
2.9B
↑ 6.96%
FY21Y/Y Change
Total Assets
15.2B
↑ 100.62%
Total Liabilities
4.5B
↑ 54.86%
FY22Y/Y Change
Total Assets
12.3B
↓ 19.48%
Total Liabilities
5.7B
↑ 26.27%
FY23Y/Y Change
Total Assets
10.1B
↓ 17.47%
Total Liabilities
4.4B
↓ 22.77%
Q4 FY22Q/Q Change
Total Assets
12.3B
↑ 8.85%
Total Liabilities
5.7B
↑ 24.93%
Q1 FY23Q/Q Change
Total Assets
11.8B
↓ 3.6%
Total Liabilities
5.1B
↓ 9.46%
Q2 FY23Q/Q Change
Total Assets
11.8B
↓ 0.31%
Total Liabilities
5.2B
↑ 1.97%
Q3 FY23Q/Q Change
Total Assets
10.1B
↓ 14.03%
Total Liabilities
4.2B
↓ 19.06%
Q4 FY23Q/Q Change
Total Assets
10.1B
↓ 0.11%
Total Liabilities
4.4B
↑ 3.36%
Q1 FY24Q/Q Change
Total Assets
10.0B
↓ 0.7%
Total Liabilities
4.3B
↓ 1.37%
FY18Y/Y Change
Operating Cash Flow
1.1B
↑ 30.51%
Investing Cash Flow
-1.8B
↑ 747.2%
Financing Cash Flow
594.0M
↓ 437.5%
FY19Y/Y Change
Operating Cash Flow
1.1B
↓ 7.97%
Investing Cash Flow
745.0M
↓ 141.09%
Financing Cash Flow
-897.0M
↓ 251.01%
FY20Y/Y Change
Operating Cash Flow
1.1B
↑ 2.76%
Investing Cash Flow
-554.0M
↓ 174.36%
Financing Cash Flow
-766.0M
↓ 14.6%
FY21Y/Y Change
Operating Cash Flow
545.0M
↓ 49.54%
Investing Cash Flow
-1.1B
↑ 92.96%
Financing Cash Flow
-51.0M
↓ 93.34%
FY22Y/Y Change
Operating Cash Flow
392.0M
↓ 28.07%
Investing Cash Flow
-591.0M
↓ 44.71%
Financing Cash Flow
1000.0M
↓ 2060.78%
Q4 FY22Q/Q Change
Operating Cash Flow
147.0M
↓ 382.69%
Investing Cash Flow
-102.0M
↓ 59.2%
Financing Cash Flow
956.0M
↑ 3314.29%
Q1 FY23Q/Q Change
Operating Cash Flow
10.0M
↓ 93.2%
Investing Cash Flow
-56.0M
↓ 45.1%
Financing Cash Flow
-473.0M
↓ 149.48%
Q2 FY23Q/Q Change
Operating Cash Flow
105.0M
↑ 950.0%
Investing Cash Flow
-37.0M
↓ 33.93%
Financing Cash Flow
-3.0M
↓ 99.37%
Q3 FY23Q/Q Change
Operating Cash Flow
139.0M
↑ 32.38%
Investing Cash Flow
-146.0M
↑ 294.59%
Financing Cash Flow
-707.0M
↑ 23466.67%

Technicals Summary

Sell

Neutral

Buy

Illumina Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Illumina Inc.
Illumina Inc.
11.0%
-16.59%
-38.65%
-76.13%
-61.02%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-3.67%
-10.34%
-15.37%
-31.35%
65.77%
Agilent Technologies Inc.
Agilent Technologies Inc.
1.42%
3.05%
5.07%
-10.16%
94.22%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
6.51%
8.62%
3.5%
12.36%
106.99%
Danaher Corp.
Danaher Corp.
6.51%
15.92%
1.97%
-6.92%
89.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
10.0%
7.5%
0.14%
-6.07%
45.29%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Illumina Inc.
Illumina Inc.
91.22
NA
4.3
3.91
-0.21
0.0
NA
36.06
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
45.67
45.67
4.75
11.06
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.63
31.63
2.7
5.2
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.71
0.14
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
48.76
48.76
3.13
6.99
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
30.13
30.13
1.33
11.19
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Illumina Inc.
Illumina Inc.
Buy
$18.5B
-61.02%
91.22
-28.71%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$38.8B
65.77%
45.67
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.9B
94.22%
31.63
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$219.4B
106.99%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$191.9B
89.83%
48.76
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.3B
45.29%
30.13
9.39%

Insights on Illumina Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.12B → 1.07B (in $), with an average decrease of 4.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -754.0M → -126.0M (in $), with an average increase of 184.1% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 43.7%

  • Vs TMO

    In the last 3 years, Illumina Inc. has experienced a drawdown of -76.1%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 65.9%

Institutional Holdings

  • Vanguard Group Inc

    11.45%

  • BlackRock Inc

    8.67%

  • State Street Corporation

    4.28%

  • Edgewood Management LLC

    4.18%

  • Baillie Gifford & Co Limited.

    3.60%

  • Loomis, Sayles & Company LP

    2.77%

Company Information

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Organization
Illumina Inc.
Employees
10590
CEO
Mr. Jacob Thaysen Ph.D.
Industry
Health Technology

Discover More

FAQs